Matrix Leads $15M Series A1 Funding In Anti-Tumor Drug Firm QnQuality

QnQuality Pharmaceuticals Ltd., a Shanghai-based drug R&D company, announces on Monday that it has raised US$15 million in a series A1 funding round led by venture capital firm Matrix Partners China and healthcare-focused venture capital company BioTrack Capital. Investment firm CASH Capital, backed by state-owned Chinese Academy of Sciences Holdings Co, Ltd., also participated in […]

Matrix Leads $15M Series A1 Funding In Anti-Tumor Drug Firm QnQuality comes originally from China Money Network. All Rights Reserved.

Read the original article: China Money Network